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Abstract 
Waldenström’s  macroglobulinemia  (WM)/
lymphoplasmacytic  lymphoma  (LPL)  is  an
indolent mature B-cell neoplasm. In rare cases
of  WM/LPL,  diffuse  large  B-cell  lymphoma
(DLBCL)  develops  as  a  result  of  histologic
transformation.  In  this  report,  we  present  a
case of DLBCL developing in a patient with
WM/LPL.  Combination  chemotherapy  for
DLBCL was effective and complete remission
was  eventually  achieved.  We  attempted  to
determine  the  clonal  relatedness  between
WM/LPL and DLBCL in the patient by analyzing
complementarity-determining  region  3
(CDR3) in the immunoglobulin heavy chain
gene. A common CDR3 sequence was found in
tumor cells of DLBCL and those of WM/LPL,
indicating that tumor cells of DLBCL are clon-
ally identical to those of WM/LPL. Therefore, in
the  present  case,  DLBCL  is  developed  from
WM/LPL cells by clonal evolution. 
Introduction
Waldenström’s macroglobulinemia (WM), a
rare B-cell neoplasm characterized by lympho-
plasmacytic cell proliferation in bone marrow
with IgM monoclonal gammopathy, is classi-
fied as a subtype of lymphoplasmacytic lym-
phoma  (LPL)  in  WHO  classification.1-3
Although WM/LPL is an indolent disorder and
the  median  overall  survival  of  patients  with
WM/LPL is in the range of 5-10 years, diffuse
large B-cell lymphoma (DLBCL) develops as a
result of histologic transformation in approxi-
mately 5-10% of patients with WM/LPL.4-6 Once
DLBCL occurs in patients with WM/LPL, the
disease course turns more aggressive. In gen-
eral,  DLBCL  developing  in  a  patient  with
WM/LPL is resistant to chemotherapy and the
prognosis  is  poorer  than  that  of  de  novo
DLBCL. Median survival from the development
of DLBCL is only 2-5 months even when combi-
nation chemotherapy for aggressive lymphoma
is applied.6
It  has  been  debated  whether  DLBCL  co-
occuring with WM/LPL develops by clonal evo-
lution  or  as  a  secondary  malignancy.  To
address  this  issue,  the  clonal  relatedness
between tumor cells of WM/LPL and those of
DLBCL  have  been  investigated  by  different
procedures. Now, the clonality of mature B-cell
neoplasm can be determined more precisely by
analyzing  complementarity  determining
region 3 (CDR3) in the immunoglobulin heavy
chain (IGH) gene by a PCR-based molecular
biological  technique.7 To  date,  three  groups
have  independently  reported  on  the  clonal
relatedness  between  tumor  cells  of  WM/LPL
and those of co-occurring DLBCL by analyzing
CDR3 sequences.8-10 One group showed clonal
identity between tumor cells of WM/LPL and
those of co-occuring DLBCL,8 while two other
groups showed that tumor cells of DLBCL are
not clonally identical to those of WM/LPL tumor
cells.9,10 In this report, we present a case of
DLBCL developing in a patient with WM/LPL.
We attempted to determine clonal relatedness
between tumor cells of WM/LPL and those of
DLBCL by analyzing CDR3 sequences.
Case Report
A  63-year-old  man  was  diagnosed  with
WM/LPL based on findings including increased
serum IgM (4823 mg/dL) with a monoclonal
component and lymphoplasmacytic cell prolif-
eration  in  bone  marrow.  He  received
chemotherapy consisted of ranimustine, vin-
desine,  melphalan,  and  prednisolone.  After
completion of the first cycle of therapy, serum
IgM level was decreased to 3058 mg/dL. Three
years after diagnosis of WM/LPL, supraclavicu-
lar lymph node swelling was found on physical
examination, and an abnormal nodular lesion
in  lung  field  was  observed  on  chest  X-ray.
Supraclavicular  lymph  node  biopsy  was  per-
formed for pathological diagnosis. Histopatho  -
logical studies on supraclavicular lymph node
revealed diffuse proliferation of large B-cells
positive for CD20, CD79a and lambda chains by
immunohistochemistry, leading to a pathologi-
cal  diagnosis  of  DLBCL  (Figure  1A  and  B).
Chemotherapy by a THP-COP regimen consist-
ing  of  cyclophosphamide,  epirubicin,  vin-
cristine,  and  prednisolone  was  initiated.
Treatment was effective and lung tumor disap-
peared and lymph node swelling was improved.
Subsequently,  complete  remission  was
achieved after the completion of six cycles of
THP-COP therapy. Five years after completion
of THP-COP therapy, when he was the age of
71-year-old,  disease  status  was  re-evaluated.
There was no sign of relapse of DLBCL, while
serum IgM level was still high, and bone mar-
row showed proliferation of lymphoplasmacyt-
ic cells (11.7% of all nucleated cells) positive
for CD79a, cytoplasmic IgM, and lambda chain
but not for CD20, without large B-cell prolifer-
ation (Figure 1C and D)
Materials and Methods
Samples and DNA extraction
Written informed consent regarding genetic
analysis of tumor cells was obtained from the
patient.  Mononuclear  cells  were  separated
from  the  bone  marrow  sample  as  described
previously.11 Genomic DNA was extracted from
bone marrow mononuclear cells using QIAamp
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DNA Blood Mini kit (QIAGEN Sciences, Hilden,
Germany)  and  from  the  paraffin-embedded
lymph  node  sample  by  using  DEPAX  kit
(TAKARA BIO., Ohtsu, Shiga, Japan) according
to the manufacturers’ instructions.
Polymerase chain reaction
Semi-nested  polymerase  chain  reaction
(PCR)  was  carried  out  to  amplify  CDR3
sequences in the IGH gene as described pre-
viously  with  minor  modifications,  using
primer  sets  Fr3A  (5’-ACACGGC[C/T]
[G/C]TGTATTACTGT -3’) and LJH (5’-TGAG-
GAGACGGTGACC-3’) for first round amplifica-
tion,  and  Fr3A  and  VLJH  (5’-
GTGACCAGGGT[A/G/C/T]  CCTTGGCCCCAG-
3’)  for  second  round  amplification.7  First
round PCR was carried out using 100 ng of
genomic DNA as a template in 50 μL of a reac-
tion mixture containing 2 μL of 10X buffer,
1.5  mM  MgCl2,  250  nM  of  each  deoxynu-
cleotide,  0.2  units  of  rTaq  DNA  polymerase
(TAKARA BIO.), and 300 nM of each primer.
Forty cycles of 94°C for 30 s, 57°C for 30 s, and
72°C for 60 s were performed. Second round
PCR  was  carried  out  using  purified  first
round PCR product as a template in 50 μL of
the  same  reaction  mixture  as  that  for  first
round PCR except for the primer sets. Forty
cycles of 94°C for 30 s, 60°C for 30 s, and 72°C
for 60 s were performed. 
Subcloning of polymerase chain
reaction products and DNA
sequencing 
Sequences of PCR products of CDR3 were
determined after subcloning as described pre-
viously.11 Briefly, PCR products were purified
with the QIAquick PCR purification kit (QIA-
GEN Sciences), and cloned into pGEM-T vec-
tor (Promega, Madison, WI, USA). After bacte-
rial  transformation,  plasmids  were  purified
and  subjected  to  sequence  determination.
Both  strands  of  each  PCR  product  were
sequenced  using  DYEnamic  ET  Dye
Terminator  sequencing  kit  (Amersham,
Buckinghamshire,  UK)  and  the  MegaBase
sequence  system  (Amersham)  according  to
the manufacturer’s instructions.  
Results
We  analyzed  sequences  of  CDR3  by  PCR
from  the  lymph  node  biopsy  specimen,  by
which the diagnosis of DLBCL was made, and
from the bone marrow sample, in which lym-
phoplasmacytic  cell  proliferation  was
observed.  PCR  products  were  cloned  into
pGEM-T  vector,  and  then  nucleotide
sequences of PCR products were determined
after subcloning. For lymph the node speci-
men,  eight  bacterial  colonies  were  isolated
and subjected to sequence analysis. Six of the
eight bacterial colonies contained the same
nucleotide  sequence  (Figure  2),  and  the
remaining  two  did  not  contain  any  CDR3
sequence. For the bone marrow specimen, 16
bacterial colonies were isolated and subjected
to sequence analysis. Six out of the 16 bacte-
rial  colonies  did  not  contain  any  CDR3
sequences.  The  remaining  ten  bacterial
colonies  contained  seven  different  CDR3
sequences  (A-G),  and  three  colonies  con-
tained “A” sequence, which is identical to the
CDR3  sequence  identified  in  lymph  node
(Table 1). Subsequently, we found a common
CDR3 sequence in DLBCL cells (lymph node)
and WM/LPL cells (bone marrow). 
Discussion
The  results  of  analysis  of  the  CDR3
sequence in the IGH gene shows clonal identi-
ty between tumor cells of WM/LPL and those of
co-occurring  DLBCL,  indicating  that  DLBCL
are originated from WM/LPL by clonal evolu-
tion in the present case. It has been debated
whether tumor cells of co-occurring DLBCL are
clonally identical to those of WM/LPL. To date,
three groups have independently reported on
the clonal relatedness between tumor cells of
WM/LPL and those of co-occurring DLBCL by
analyzing CDR3. Similar to the present result,
Nakamura  et  al.  showed  clonal  identity
between tumor cells of WM/LPL and those of
co-occurring  DLBCL.8 On  the  other  hand,
Shimizu et al. and Tojo et al. showed clonal dif-
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Figure 1. Histopathology of lymph node and bone marrow tissues. A) In lymph node,
proliferation of large tumor cells with diffuse pattern is observed (HE staining X400); B)
and tumor cells are positive for CD20 (Immunohistochemistry, X400). C) In bone mar-
row, proliferation of lymphoplasmacytic cells is observed (HE staining, X400); D) and
these cells are positive for CD79a (Immunohistochemistry, X400).  
Figure 2. Sequence analysis of CDR3 in lymph node. Arrows indicate primer sequences
of Fr3A and VLJH.   [page 30] [Hematology Reports 2011; 3:e10]
ference  between  tumor  cells  of  DLBCL  and
those  of  WM/LPL,  suggesting  that  DLBCL
develops independently as a second neoplasm
in patients with WM/LPL.9,10 Collectively, these
discordant results suggest that there are two
different pathways of development of DLBCL in
patients with WM/LPL: clonal evolution or the
development of a second neoplasm. Histologic
transformation occurs in other types of indo-
lent B-cell neoplasms, including chronic lym-
phocytic  leukemia  (CLL).  Clonal  relatedness
between tumor cells of co-occuring DLBCL and
those  of  CLL  has  been  investigated  more
extensively,  and  the  results  indicate  that
DLBCL can develop either by clonal evolution
or as a secondary neoplasm.12,13 In the majori-
ty of patients with CLL, DLBCL occurs by clon-
al evolution, suggesting that clonal evolution is
a major pathway of the development of DLBCL
in cases of CLL.12,13 Similar to CLL, in cases of
WM/LPL, DLBCL develops by these two path-
ways,  although  it  is  not  clear  which  of  two
pathways is dominant in the development of
DLBCL in WM/LPL. 
The molecular mechanism of the develop-
ment of DLBCL by clonal evolution in WM/LPL
has not been elucidated. In the case of CLL,
several different events, including additional
genetic  alterations,  and  viral  infection,  may
trigger clonal evolution.13-16 For instance, the
acquisition  of  p53 tumor  suppressor  gene
mutation and/or chromosome 17p13 deletion,
and  c-MYC  alterations  frequently  occur  in
tumor cells during histologic transformation to
DLBCL.13,14,17 Epstein-Barr virus infection has
been  identified  in  lymphoma  cells  in  a  few
patients  with  co-occurring  aggressive  lym-
phoma with CLL.18 Similar events may occur
during clonal evolution in DLBCL development
in patients with WM/LPL. Further investigation
is necessary. 
It is also important to clarify whether there
are any differences in biological behaviors of
tumor  cells  and  clinical  features  between
DLBCL developed by clonal evolution and that
developed  as  a  secondary  neoplasm.  Once
DLBCL develops in WM/LPL patients, the dis-
ease course turns more aggressive. In general,
the response to chemotherapy is not good and
median  overall  survival  is  only  3-5  months,
even  when  multi-agent  chemotherapy  is
applied.6 The  introduction  of  rituximab  to
chemotherapy may improve the treatment out-
come  of  DLBCL  developed  in  WM/LPL
patients.19,20 When the patient in the present
case  received  therapy  for  DLBCL,  rituximab
had not been available in Japan. Combination
chemotherapy (THP-COP therapy) without rit-
uximab was, however, effective for DLBCL, and
the  patient  eventually  achieved  complete
remission and maintained it for approximately
five years. Interestingly, as described in report
by Nakamura et al., a patient with co-occurring
DLBCL caused by tumor cells clonally identical
to  WM/LPL  achieved  complete  remission  by
combination  chemotherapy.8 In  contrast,  as
described in reports by Shimizu et al. and Tojo
et al., patients with DLBCL caused by different
clones from those of WM/LPL showed poorer
prognosis, and died within several months.9,10
However, the number of analyzed cases is too
small  to  clarify  clinical  implication  of  clonal
relatedness. Currently, Rossi et al. performed
comprehensive  molecular  study  including
analysis of clonal relatedness of tumor cells of
CLL and co-occurring DLBCL, indicating that
clonally unrelated cases are clinically and bio-
logically  distinct  from  clonally  related  cases,
and  are  characterized  by  better  clinical  out-
comes.13 It is not clear whether clinical signif-
icance  of  clonal  relatedness  between  tumor
cells of co-occurring DLBCL and original tumor
cells in WM/LPL is different from that in CLL. It
is necessary to accumulate cases of DLBCL co-
occurring with WM/LPL and to analyze correla-
tion between clinicopathological features and
clonal relatedness. 
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